Show simple item record

dc.contributor.authorHawkins, Robert E
dc.contributor.authorJiang, Y.
dc.contributor.authorLorigan, Paul C
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorPillai, Manon
dc.contributor.authorThomas, M.
dc.contributor.authorKirillova, N.
dc.contributor.authorBridgeman, J. S.
dc.contributor.authorKueberuwa, G.
dc.contributor.authorGuest, R. D.
dc.contributor.authorRoberts, Z. J.
dc.date.accessioned2022-08-17T09:45:47Z
dc.date.available2022-08-17T09:45:47Z
dc.date.issued2021en
dc.identifier.citationHawkins RE, Jiang Y, Lorigan PC, Thistlethwaite FC, Pillai M, Thomas M, et al. Clinical feasibility and treatment outcomes with unselected autologous tumour-infiltrating lymphocyte (TIL) therapy in patients with advanced cutaneous melanoma. Human Gene Therapy. 2021 Oct;32(19-20):A7-A8. PubMed PMID: WOS:000811305600016.en
dc.identifier.urihttp://hdl.handle.net/10541/625479
dc.language.isoenen
dc.titleClinical feasibility and treatment outcomes with unselected autologous tumour-infiltrating lymphocyte (TIL) therapy in patients with advanced cutaneous melanomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentInstil Bio, Inc., Tarzana, CA;en
dc.identifier.journalHuman Gene Therapyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record